Nivolumab (Opdivo) plus relatlimab (Opdualag) significantly improves progression-free survival (PFS) in advanced melanoma compared with anti–PD-1 monotherapy alone, according to three-year descriptive results of the RELATIVITY-047 trial that confirm the combination’s sustained benefit.
Health Professionals
New Study Identifies Potential Genes Implicated in Treatment-Resistant Melanoma
Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine.
Over a quarter of stem cell transplant survivors develop cutaneous malignant neoplasms
More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.
Dr Ascierto on First-Line Treatment Selection in Advanced BRAF+ Melanoma
Paolo A. Ascierto, MD, director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses treatment sequencing considerations for patients with advanced BRAF-mutant melanoma, based on findings from the phase 2 SECOMBIT (NCT02631447) and phase 3 DREAMseq (NCT02224781) trials.